


# Quality of Life and Work Impacts among Caregivers of Patients with Chronic Myeloid Leukemia (CML) – A Caregiver Survey in the US

Kathryn E. Flynn<sup>1</sup>, Joan Clements<sup>2</sup>, Karen DeMairo<sup>3</sup>, Jennifer Hiller<sup>4</sup>, David Wei<sup>5</sup>, Nisha C Hazra<sup>6</sup>, Cristina Constantinescu<sup>7</sup>, Yan Meng<sup>6</sup>, Dominick Latremouille-Viau<sup>8</sup>, Gabriel Marquez<sup>9</sup>, Daisy Yang<sup>5</sup>, Andrea Damon<sup>5</sup>, Islam Sadek<sup>5</sup>, Annie Guérin<sup>8</sup>, Kelly Schoenbeck<sup>10</sup>

<sup>1</sup>Medical College of Wisconsin, Department of Medicine, US; <sup>2</sup>CML Buster Foundation, US; <sup>3</sup>The Leukemia & Lymphoma Society, US; <sup>4</sup>Manton, CA, US; <sup>5</sup>Novartis Pharmaceuticals Corporation, US; <sup>6</sup>Analysis Group, Ltd., UK; <sup>7</sup>Ipsos, Switzerland; <sup>8</sup>Analysis Group, Inc., Canada; <sup>9</sup>Novartis Pharmaceuticals Corporation, Ireland; <sup>10</sup>University of California San Francisco, Division of Hematology and Oncology, US

## KEY FINDINGS & CONCLUSIONS

- Caring for patients with CML, especially when those patients experience AEs, imposes a significant burden on caregivers, resulting in high work productivity impairment and decreased quality of life
- Caregiver burden when caring for patients with CML is as extensive as caring for patients with other cancers
- Findings from this study highlight the need for more tolerable treatment to lessen the burden of caregivers and address their unique challenges in CML management



Scan to obtain:

- Poster
- Plain language summary
- Slides
- Supplementary material

<https://tinyurl.com/FlynnPS2286>

Copies of this poster obtained through Quick Response (QR) code are for personal use only and may not be reproduced without permission of the authors.

This study is sponsored by Novartis Pharma AG. Poster presented at the European Hematology Association (EHA) Congress, June 12-15, 2025, Milan, Italy

BACKGROUND & OBJECTIVES

- Caregivers play a pivotal role in the management of patients with CML, which may be accompanied by emotional or physical burden and impact on their work productivity
- The patients they care for with CML treated with tyrosine kinase inhibitors (TKIs) often experience intolerance associated with adverse events (AEs) which may add to the caregiver burden<sup>1</sup>
- This study assessed the level of caregiver burden and evaluated the impact of TKI-related AEs experienced by patients with CML on the quality of life (QoL) of their caregivers using caregiver-reported outcomes

## RESULTS

